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OBJECTIVE — To determine the speciﬁc monoﬁlament examination score that predicts the
subsequent 4-year incidence of diabetic neuropathy with the highest degree of diagnostic
accuracy.
RESEARCH DESIGN AND METHODS — Longitudinal follow-up of 175 of 197 (89%)
participants in the Toronto Diabetic Neuropathy Cohort without baseline neuropathy for inci-
dentneuropathy.Weexaminedthebaselinemonoﬁlamentexaminationscore(andothersimple
sensory screening tests) by receiver operating characteristic (ROC) curve analysis.
RESULTS — Incident diabetic neuropathy developed in 50 (29%) participants over a mean
follow-up of 4.1 years (interquartile range 2.6–7.1 years). Although male sex, longer diabetes
duration, taller height, and higher blood pressure at baseline were associated with incident
neuropathy, the strongest association was with a lower baseline monoﬁlament score (score out
of 8 was 3.7  2.5 for incident neuropathy vs. 5.7  2.3 for those who did not develop
neuropathy; P  0.001). The optimal threshold score for risk of incident neuropathy was 5
sensate stimuli out of 8, with 72% sensitivity, 64% speciﬁcity, positive and negative likelihood
ratios of 2.5 and 0.35, and positive and negative predictive values of 87 and 46%, respectively
(
220.7,P0.001).AreaundertheROCcurvewassigniﬁcantlygreaterforthemonoﬁlament
examination compared with that for other simple sensory tests.
CONCLUSIONS — A simple threshold of 5 sensate stimuli out of 8 discriminates 4-year
risk of diabetic neuropathy with acceptable operating characteristics. Although there are limi-
tationsinitsspeciﬁcityforpredictionoffutureneuropathyonset,themonoﬁlamentexamination
is appropriate as a simple diabetic neuropathy screening instrument generalizable to the clinical
setting.
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T
he diffuse injury to peripheral nerves,
deﬁned as diabetic sensorimotor
polyneuropathy but commonly re-
ferredtoas“diabeticneuropathy,”hasex-
ceptionally high incidence (1) and is
observed in up to 50% of people with
diabeteswhenevaluatedusingobjective
tests such as nerve conduction studies
(2). It represents a progressive, diffuse,
and length-dependent process of nerve
injury, involving factors other than
simple exposure to hyperglycemia (1).
It begins with a long subclinical la-
tency period whose identiﬁcation and
management is challenging; notwith-
standing,itisimportanttoidentifyneu-
ropathy in its earliest stages because it
may progress to produce extreme mor-
bidity and health care costs (3,4). Valid
identiﬁcation at early stages will proba-
bly provide the best opportunity for ef-
fective intervention.
Atpresent,underdiagnosisofdiabetic
neuropathy is a fundamental issue: it im-
pedes the beneﬁts of early identiﬁcation,
impedes the emphasis on early manage-
ment necessary to improve glycemic con-
trol, and impedes the prevention of
neuropathy-related sequelae (5). That
practice recommendations for screening,
such as examination with the monoﬁla-
ment or vibration tuning fork, are not be-
ing systematically carried out contributes
totheissueofunderdiagnosisandmaybe
related to challenges with applicability of
a screening test in clinical practice (6).
Whereas measurement of microalbumin-
uria and funduscopic examinations serve
as objective tests for incipient nephropa-
thy and retinopathy in type 1 diabetes,
evidence for the validity of a comparably
objective test is lacking for neuropathy.
The Semmes-Weinstein 10-g monoﬁl-
ament examination is a simple, practical,
and accurate tool for diabetic neuropathy
screening. It involves a hand-held cali-
brated nylon thread that buckles once it
has delivered a force of 10 g; in this way,
when applied to the skin surface, it pro-
vides a standardized measure of a pa-
tient’s ability to sense a point of pressure.
Although ﬁrst studied as a speciﬁc prog-
nostic indicator for skin infection, ulcer-
ation, and amputation (7,8), it has been
studied for identiﬁcation of diabetic neu-
ropathy (9–12). In the study with the
highest level of evidence for identifying
the presence of diabetic neuropathy, a
scoreof7or8correctresponsesoutof8
was associated with 78% sensitivity,
whereas a score of 3 correct responses
was associated with 96% speciﬁcity
(10,12). The monoﬁlament examina-
tion became part of clinical practice
guidelines on the basis of this concur-
rent validity (13).
The most relevant question is
whether the monoﬁlament score can rep-
resent incipient nerve injury before the
development of clinically recognized dia-
betic neuropathy; that is, does the mono-
ﬁlament examination have sufﬁcient
predictive validity? Guided by this con-
sideration, we monitored for a mean of 4
years patients with diabetes but without
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto,
Toronto, Ontario, Canada; and the
2Division of Neurology, Department of Medicine, University of
Toronto, Toronto, Ontario, Canada.
Corresponding author: Bruce A. Perkins, bruce.perkins@uhn.on.ca.
Received 2 October 2009 and accepted 20 March 2010. Published ahead of print at http://care.
diabetesjournals.org on 31 March 2010. DOI: 10.2337/dc09-1835.
B.A.P., A.O., and V.B. had full access to all of the data in the study and take responsibility for the integrity of
the data and the accuracy of the data analysis.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Pathophysiology/Complications
ORIGINAL ARTICLE
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1549neuropathy for the future onset of dia-
beticneuropathythroughtheTorontoDi-
abetic Neuropathy Cohort (10,12). To
ourknowledge,itrepresentstheonlypro-
spective observational study designed to
assess the predictive validity (the validity
in identifying future risk of neuropathy
onset) of a simple screening test for dia-
betic neuropathy.
RESEARCH DESIGN AND
METHODS— Subjects without dia-
betic neuropathy in the ﬁrst cross-
sectional examination of the Toronto
DiabeticNeuropathyCohortwereeligible
for the current study (10,12). The proto-
col and consent procedures were ap-
proved by the Multidisciplinary Research
Ethics Board of the Toronto General Hos-
pital Research Institute.
From 1999 and 2001, 478 subjects
were examined as part of the Toronto Di-
abetic Neuropathy Cohort, a cross-
sectional study investigating the
concurrent validity of screening tests
(10,12). A clinical stratiﬁcation method
based on the Toronto Clinical Neuropa-
thy Score was used in the accrual of this
cohort to ensure that it would consist of
subjects with a broad spectrum of nerve
injury (10,14). Four severity strata, in-
cludingnoneuropathy,mildneuropathy,
moderate neuropathy, and severe neu-
ropathy, were graded according to the
score quartiles, and accrual of subjects
into the study was terminated only when
the smallest stratum contained 50 sub-
jects. A comprehensive evaluation was
also conducted to exclude risk of neurop-
athyfromotheretiologiessuchasfamilial,
alcoholic, nutritional, and uremic poly-
neuropathy. The 51 nondiabetic refer-
ence subjects in the total cohort of 478
were excluded from the current analysis.
Of the remaining 427 subjects with dia-
betes (65 type 1 and 362 type 2 diabetes),
197 did not meet the diagnostic criteria
for diabetic neuropathy and were thus el-
igible for study. We were able to reevalu-
ate 175 of the 197 subjects (89%) from
2004 until 2007 using the same clinical
and electrophysiological examination to
identify incident cases of diabetic
neuropathy.
Determination of the monoﬁlament
score and other sensory screening
test scores
The monoﬁlament examination was per-
formedbilaterallyusinga10-g(size5.07)
monoﬁlament according to previous
study (10,12). In brief, ﬁrst a reference
stimulus was applied to the forehead or
the sternum. With the patient’s eyes
closed,themonoﬁlamentwasappliedtoa
noncallused site on the dorsum of the
great toe just proximal to the nail bed us-
ing a smooth motion: the skin was
touched and the monoﬁlament was bent
for a full second and then lifted from the
skin.Thismaneuverwasrepeated4times
per foot in a random arrhythmic manner.
The responses were tallied to produce a
scorerangingfrom0to8(normal[1point
assigned],decreased[0.5pointassigned],
orabsent[0pointsassigned])Ascoreof0
represented a complete lack of percep-
tion, whereas a score of 8 represented full
perception of all stimuli. Inter- and in-
trarater reproducibility was very good to
excellent for the performance of the
monoﬁlament examination according to
this protocol (10). Superﬁcial pain sensa-
tion was measured using a sterile Neu-
rotip (Owen Mumford, Oxford, U.K.)
applied four times to the same sites, and
the score (from 0 to 8) was deﬁned as the
total number of times the application of
the pain sensation was perceived. Vibra-
tion testing by the on-off method was
conducted using a 128-Hz tuning fork
applied to the bony prominence at the
dorsumoftheﬁrsttoejustproximaltothe
nail bed. The patient reported perception
of both the start of the vibration sensation
and the cessation on dampening, con-
ducted twice on each toe, and the score
(between0and8)wasdeﬁnedasthetotal
number of times application and damp-
ening were felt. Vibration testing by the
timed method was measured by the pa-
tientreportingthetimeatwhichvibration
diminished beyond perception. The tun-
ing fork was then applied to the dorsal
aspect of the distal phalanx of the exam-
iner’s thumb. The time (in seconds) at
which vibration sensation diminished be-
yond the examiner’s perception was then
added from both sides to provide a single
score. Vibration perception threshold
(VPT) testing was measured quantita-
tively by the method of limits using the
Medoc device (Medoc Advanced Medical
Systems, Durham, NC). Each test was
performed by an examiner blinded to re-
sults of all other examinations.
Determination of incident diabetic
neuropathy: the reference standard
Incident diabetic neuropathy was deﬁned
by clinical and electrophysiological crite-
ria according to the consensus of the
American Association of Neurology, the
American Academy of Electrodiagnostic
Medicine, and the American Academy of
Physical Medicine and Rehabilitation
(15). Based on this consensus, incident
case deﬁnition generally required the
presenceofelectrophysiologicalpolyneu-
ropathy as deﬁned by abnormality of
three or more parameters in two or more
nerves in combination with the presence
of more than one neuropathic symptom
or sign of peripheral neuropathy. This
same criterion was used to both exclude
the presence of diabetic neuropathy at
baseline and to deﬁne incident neuropa-
thy during follow-up.
For the electrophysiological compo-
nent of incident case deﬁnition, evalua-
tion of the unilateral median, ulnar,
peroneal, tibial, and sural nerves was
performed at baseline and subsequent
examinations were performed using stan-
dardized nerve conduction studies (16).
ThesewereperformedusingtheCounter-
point instrument (Natus Medical, San
Carlos, CA) according to the standards of
the American Association for Neuromus-
cular and Electrodiagnostic Medicine and
the Canadian Society of Clinical Neuro-
physiology. Low interobserver and in-
traobserver variabilities have been
observed for these measurements using
the techniques described (17). Individual
nerveconductionparameterswerescored
as normal or abnormal according to labo-
ratory reference values.
Statistical analysis
Analyses were performed in SAS (version
9.1 for Windows). Using the methods for
power calculation in the ROC analysis of
Hanley and McNeil (18), given a type 1
error ( level) of 0.05, we anticipated
94.5% power to discriminate an area un-
der the curve from the null hypothesis in
which the diagnostic accuracy is no dif-
ferent from chance alone (area under the
curve [AUC]  0.5) under the assump-
tion that incident diabetic neuropathy
would occur in approximately one-third
of diabetic individuals. Differences in
baseline characteristics between individ-
uals with incident cases of diabetic
neuropathy and control subjects were as-
sessed using 
2 tests for categorical vari-
ables. For these differences in baseline
characteristics,continuousvariableswere
compared using the two-sided Mann-
Whitney U test (Wilcoxon rank-sum test)
because some variables (height, in
meters) were not normally distributed.
Signiﬁcance was based on an  level of
0.05. We also pursued a multivariate lo-
gistic regression model to determine clin-
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associated with future diabetic symmetri-
cal polyneuropathy (DSP) onset. In this
model, the dependent variable was DSP
case-control status, and the independent
variableswereage,sex,diabetesduration,
BMI, diastolic blood pressure, A1C, and
the monoﬁlament score. This logistic re-
gression model was associated with seven
events per independent variable and a 
2
value in a log-likelihood test of 27.1 (P 
0.007). To obtain the AUC and optimal
decision threshold level for incident neu-
ropathy, a receiver operating characteris-
tic (ROC) curve was generated (19). The
positive monoﬁlament score result was
deﬁned by the threshold equal to or be-
low the threshold determined from ROC
curve analysis by visual inspection. Com-
parisonsoftheAUCforthemonoﬁlament
score and the other screening tests were
based on the method of Pencina et al.
(20). In the absence of a validation set, a
bootstrap analysis consisting of 1,000
datasets produced by the random selec-
tionof175subjectswithreplacementwas
performedandanalyzedformeanAUCof
each sensory test.
RESULTS— The 175 subjects were
examined for a second evaluation a mean
of 4.1 years after baseline examination.
This distribution was skewed to the right
with an interquartile range of 2.6 to 7.1
years. Among those with incident DSP,
the median follow-up was 3.9 years (in-
terquartile range 2.5–7.1 years), whereas
for those without incident DSP it was 4.3
(interquartilerange2.5–7.1years),witha
Wilcoxon rank-sum two-sided test P
value of 0.35. The clinical characteristics
of the 22 eligible subjects who we were
unable to reexamine did not differ from
those of subjects who were examined. In-
cident diabetic neuropathy developed in
50 (29%) of the 175 subjects. In none of
the subjects was polyneuropathy owing
to nondiabetic causes recognized.
The characteristics of the 175 study
subjects at the time of baseline evaluation
are summarized in Table 1, according to
the absence or presence of incident dia-
beticneuropathyattheﬁnalexamination.
Incident diabetic neuropathy occurred
more frequently in male subjects. Al-
though no age differences were seen, case
subjects had signiﬁcantly longer diabetes
duration. No differences in diabetes type,
smoking, or alcohol consumption were
observed at baseline between subjects
with incident cases and their control sub-
jects. Height, weight, and BMI were sim-
ilarbetweencaseandcontrolsubjects,yet
both systolic and diastolic blood pressure
values were signiﬁcantly higher in sub-
jects with incident cases of diabetic neu-
ropathy. Differences between subjects
with incident cases and control subjects
without onset of neuropathy were ob-
served for the baseline monoﬁlament
score and the VPT values. To further ex-
plore these observations, we pursued a
multivariatemodelthatincludedallofthe
variables listed in the table, including
those likely to be collinear (the simple
screening tests and VPT testing scores). A
lower baseline monoﬁlament score was
the only variable independently associ-
ated with neuropathy incidence (
2 10.5;
P0.0012).Byusingthemedianvalueof
thescoretodetermineoddsratiosforrisk,
the adjusted odds ratio for incident dia-
beticneuropathyassociatedwithamono-
ﬁlamentscore5comparedwith5was
5.5 (95% CI 1.9–15.9). Although dem-
onstrating a trend toward higher values
among subjects with incident cases of di-
abetic neuropathy, the baseline A1C val-
ues were not signiﬁcantly different either
in the univariate or adjusted compari-
sons. The duration of time between base-
line and follow-up examinations did not
differ between case and control subjects.
In view of the strong odds ratio ob-
served for the monoﬁlament score, we
pursuedROCcurveanalysistodetermine
theoptimalthresholdscoreforprediction
of 4-year incident diabetic neuropathy.
Table1—Baselinecharacteristicsofthe175subjectsaccordingtothe4-yearincidentdiabetic
neuropathy
Characteristic
Incident diabetic neuropathy
P value* Absent Present
n 125 50
Age at baseline (years) 56  85 7  8 0.08
Male sex (%) 78 (62) 40 (80) 0.03
Type 2 diabetes (%) 106 (85) 41 (82) 0.65
Diabetes duration (years) 11  91 5  9 0.02
Current/past smoking (%) 68 (54) 28 (56) 0.65
Alcohol consumption 3
equivalents/day 17 (14) 7 (14) 0.96
Diabetes therapy
Insulin use 50 (40) 24 (48) 0.38
Oral hypoglycemic agent use 63 (55) 26 (52) 0.38
ACE inhibitor agents† 28 (22) 18 (36) 0.14
Retinopathy history‡ 18 (14) 11 (22) 0.19
Nephropathy history‡ 8 (16) 9 (18) 0.89
Foot ulcer history‡ 6 (5) 3 (6) 0.88
Height (m) 1.69  0.09 1.73  0.07 0.10
Weight (kg) 82.8  14.6 86.5  16.5 0.73
BMI (kg/m
2) 29.0  4.7 29.0  5.1 0.57
Systolic blood pressure (mmHg) 132  15 139  14 0.04
Diastolic blood pressure (mmHg) 82  88 6  8 0.05
A1C (%) 8.2  1.5 8.6  1.3 0.22
Monoﬁlament score 0.001
Mean  SD 5.7  2.3 3.7  2.5
Interquartile range 4.0–8.0 1.5–5.5
Other screening test scores
Vibration by the on-off method
(score 0–8) 6.5  2.4 5.5  3.0 0.03
Vibration by the timed method
(in seconds) 28  13 34  14 0.02
Superﬁcial pain score
(score 0–8) 6.5  2.2 5.5  3.0 0.04
VPT (m) 21.9  14.8 30.5  15.3 0.001
Data are means  SD or n (%) unless otherwise indicated. *Categorical variables report P values for 
2 test
statistics. Although continuous variables were generally normally distributed except for height, we report P
values for the two-sided Mann-Whitney U Test (Wilcoxon rank-sum test). †ACE inhibitor agents. The most
commonly used agents were ramipril, enalapril, and lisinopril, respectively. ‡By subject self-report.
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monoﬁlament score is represented by the
solidblacklineinFig.1.Thecombination
of an optimal sensitivity of 72% and opti-
mal speciﬁcity of 64% was observed at a
cutoff level for positivity of 5 sensate
stimuli out of 8. This threshold was asso-
ciated with 38 true positives out of 50
incident cases of diabetic neuropathy and
81 true negatives of 125 control subjects.
Thus, the calculated positive predictive
value at this cutoff level was only 46%,
whereas the negative predictive value was
87%. Positive and negative likelihood ra-
tios were 2.5 and 0.35, respectively. The
AUC was 0.71 (95% CI 0.66–0.72) for
the monoﬁlament score, which exceeded
that of the other simple sensory tests and
VPTtestingshowninFig.1.Asdetailedin
Table 2, the AUC for the monoﬁlament
score was signiﬁcantly greater than the
AUC for the other tests. In the absence of
a validation set, bootstrap analysis was
performed,whichparalleledtheresultsof
the derivation set.
CONCLUSIONS — In a cohort of
175 diabetic subjects with the absence of
diabetic neuropathy, the 4-year risk of in-
cident diabetic neuropathy was high (50
cases, 29%). Among all the measured
clinical and biochemical variables, the
strongest independent association was
observed with a lower baseline monoﬁla-
mentexaminationscore.InROCanalysis,
the AUC, as a measure of overall diagnos-
ticaccuracy,surpassedthoseofothersim-
ple screening tests and quantitative VPT
testing. The optimal threshold monoﬁla-
ment score for the prediction of neurop-
athy incidence was a score of 5 correct
responses out of 8. This threshold was
associated with very good sensitivity
(72%) and negative predictive value
(87%), implying that the ﬁnding of a neg-
ativetestresult,amonoﬁlamentscore5
correct responses out of 8, implies the
lowest4-yearriskfortheonsetofneurop-
athy. This sensitivity highlights the major
advantage of the monoﬁlament examina-
tion in clinical practice, which is to rule
out subsequent risk of disease in those
without neuropathy. However, this ad-
vantage is limited by a lower speciﬁcity
and positive predictive value (65 and
46%, respectively), indicating that the
monoﬁlament score cannot conﬁdently
rule in risk of disease. Rather, the mono-
ﬁlament score can be used to rule out
such risk, which ultimately is the neces-
sary characteristic of a routine screening
test.
Of critical importance in the clinical
care of patients with diabetes is the pro-
cessofriskstratiﬁcationfordiabetescom-
plications at a preclinical stage when
injury is absent or incipient and when
clinical interventions are most likely to be
effective for prevention of progression to
advanced injury. For example, urinary al-
bumin excretion is a quantitative variable
for which a speciﬁc range of values,
termed microalbuminuria, has become
ﬁrmly entrenched in clinical practice as it
is seen as a marker of incipient renal in-
jury in diabetes (21). Identiﬁcation of mi-
croalbuminuria permits interventions
that are designed to prevent progression
to advanced kidney disease, years before
its development. Conversely, identiﬁca-
Figure 1—ROC curve for 4-year incident diabetic neuropathy in the 175 subjects with diabetes.
TheROCcurveforthemonoﬁlamentexaminationisindicatedbythesolidblackline.Thepointon
this curve that indicates a combination of maximal sensitivity and the lowest false-positive rate
(false-positive rate is mathematically equivalent to 1  speciﬁcity) is indicated by the arrow and
deﬁnesthethresholdvalueforpositivityat5correctresponsesoutof8.Suchascoreisassociated
with72%sensitivityand64%speciﬁcity.Theareaunderthecurvewas0.71(95%CI0.66–0.72).
See Table 2 for estimates of AUC for each test.
Table 2—Comparison of area under the ROC curve between the monoﬁlament score and the
other screening test scores
Test
Area under the
ROC curve P value*
Bootstrap analysis
(1,000 datasets)
Mean AUC
(95% distribution) P value†
Monoﬁlament 0.71 — 0.71 (0.62, 0.80) —
Other simple tests
Vibration by the on-off method 0.59 0.007 0.59 (0.50, 0.67) 0.0001
Vibration by the timed method 0.61 0.008 0.61 (0.52, 0.70) 0.0001
Superﬁcial pain score 0.57 0.0001 0.57 (0.48, 0.66) 0.0001
Quantitative tests
VPT 0.67 0.094 0.67 (0.59, 0.76) 0.0001
*PvalueforcomparisonwiththeAUCforthemonoﬁlamentscore,accordingtothemethodofPencinaetal.
(20). †Student t test P value for comparison with the AUC for the monoﬁlament score.
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albuminuria,servestoidentifythoseindi-
vidualswiththelowestsubsequentriskof
diabetic nephropathy. However, the lon-
gitudinal clinical studies that are neces-
sary for identifying a comparable marker
of incipient nerve injury are insufﬁcient.
The current evidence for neuropathy is
only supported by cross-sectional studies
(10–13,22,23).
With the aim of ﬁnding the compara-
ble marker of incipient nerve injury, we
chose to evaluate the quantitative mono-
ﬁlament score. Previous work had dem-
onstratedincross-sectionalanalysisthata
monoﬁlament score of 7 correct re-
sponses out of 8 had high sensitivity
(77%), whereas a score of 3 correct re-
sponses out of 8 had very high speciﬁcity
(96%) for the concurrent presence of di-
abetic neuropathy (10). The question re-
mained whether a single score or range of
scores in between these two thresholds
could represent incipient nerve injury.
The current analysis was designed to an-
swer this speciﬁc question by identifying
a large group of subjects without diabetic
neuropathy and to determine the operat-
ing characteristics of the monoﬁlament
score for the 4-year incidence of neurop-
athy. Because a score of 3 correct re-
sponsesoutof8,associatedwithpresence
of neuropathy in the cross-sectional
study, was uncommon in the current
study (18% of participants), we can inter-
prettheresultsofboththecross-sectional
and longitudinal study together: When
the monoﬁlament examination is applied
as a screening test, a score of 3 correct
responses out of 8 indicates a very high
likelihood of current diabetic neuropa-
thy. A score of 4–5 correct responses out
of 8 indicates incipient neuropathy. Sub-
jectswiththesescoresareunlikelytohave
neuropathy at the time of examination
but, rather, have a high 4-year risk of its
incidence. In clinical practice, knowledge
of this risk might help motivate attain-
ment of glycemic targets as glycemic con-
trol is the only known disease-modifying
intervention for DSP. For research into
disease-modifying therapies, subjects
with such scores could be accrued as
high-risk subjects for inclusion in clinical
trials. The remaining scores of 6–8 cor-
rectresponsesoutof8indicatebothalack
of neuropathy and the lowest 4-year risk
of its incidence.
The theoretical comparisons between
the monoﬁlament examination and as-
sessmentofurinaryalbuminexcretionex-
tend to the performance characteristics of
these two tests. The low positive predict-
ive value of the monoﬁlament score
thresholdof5correctresponsesoutof8
(the upper threshold for incipient nerve
injury) is in fact very consistent with the
low positive predictive value for mi-
croalbuminuria (24). Despite this limita-
tion, assessment of microalbuminuria
remains a standard of diabetes care, ow-
ing to the beneﬁt of its sensitivity. Simi-
larly, we view the beneﬁt of the
monoﬁlament examination as a screening
test for diabetic neuropathy to be attrib-
utable to its sensitivity.
Although unique as a longitudinal
study of predictive validity in diabetic
neuropathy, there are potential limita-
tions to the interpretation of the results of
thisstudy.First,thestudygroupincluded
a mixed cohort of type 1 and type 2 dia-
betic subjects, which makes an assump-
tion that diabetic neuropathy and its
clinical assessment are consistent be-
tweendiabetestypes.Second,theinterval
of time between baseline and ﬁnal evalu-
ation of the participants in this study was
variable,butwewerenotabletodetectan
inﬂuence of follow-up time on the likeli-
hood of incident diabetic neuropathy.
Third, we explored our hypothesis in a
derivation set without access to a valida-
tion set. To address this issue of certainty,
we performed a bootstrap analysis. Fi-
nally, the reference standard deﬁnition of
diabeticsensorimotorpolyneuropathyre-
mains challenging as it combines clinical
and electrophysiological criteria that are
not consistently aligned in individual
subjects. To overcome this feature of the
deﬁnition as much as possible, we used
the most up-to-date deﬁnition of neurop-
athy (15).
Knowledge of the monoﬁlament
score permits general risk stratiﬁcation of
patients for future incident neuropathy.
Our ﬁndings demonstrate that the mono-
ﬁlament examination, a valid and clini-
cally feasible biomarker for diabetic
neuropathy in cross-sectional study, also
has sufﬁciently valid operating character-
istics as a marker of incipient nerve injury
in longitudinal study. Thus, the quantita-
tive monoﬁlament score can be used to
identify those at the lowest and highest
4-year risk of diabetic neuropathy inci-
dence. In this capacity it is aligned with
other clinical tests for diabetes complica-
tions and is limited by suboptimal speci-
ﬁcity. To further reﬁne risk prediction of
diabetic neuropathy in clinical practice,
evaluation of future novel biomarkers of
diabetic neuropathy must aim to report
the results of longitudinal evaluation for
predictive validity and compare these to
the operating characteristics reported
here for the monoﬁlament examination.
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